Daily Stock Analysis, NBRV, Nabriva Therapeutics PLC, priceseries

Nabriva Therapeutics PLC. Daily Stock Analysis
Stock Information
Open
0.43
Close
0.45
High
0.46
Low
0.41
Previous Close
0.43
Daily Price Gain
0.02
YTD High
0.71
YTD High Date
Jan 4, 2022
YTD Low
0.40
YTD Low Date
Mar 1, 2022
YTD Price Change
-0.23
YTD Gain
-34.43%
52 Week High
2.33
52 Week High Date
Mar 17, 2021
52 Week Low
0.40
52 Week Low Date
Mar 1, 2022
52 Week Price Change
-1.31
52 Week Gain
-74.66%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 7. 2016
43.10
Jan 31. 2017
80.48
35 Trading Days
86.74%
Link
LONG
Feb 7. 2017
85.00
Mar 10. 2017
116.73
22 Trading Days
37.33%
Link
LONG
Mar 4. 2019
21.30
Mar 26. 2019
28.03
16 Trading Days
31.60%
Link
LONG
May 9. 2019
24.30
May 17. 2019
25.88
6 Trading Days
6.51%
Link
LONG
Jun 26. 2019
21.70
Jul 16. 2019
23.29
13 Trading Days
7.32%
Link
LONG
Sep 6. 2019
20.60
Sep 17. 2019
23.60
7 Trading Days
14.57%
Link
LONG
Feb 10. 2020
13.80
Feb 24. 2020
14.71
9 Trading Days
6.57%
Link
LONG
May 18. 2020
6.09
Jun 1. 2020
8.15
9 Trading Days
33.68%
Link
LONG
Jan 6. 2021
2.62
Jan 26. 2021
2.98
13 Trading Days
13.76%
Link
Company Information
Stock Symbol
NBRV
Exchange
NasdaqGS
Company URL
http://www.nabriva.com
Company Phone
(610) 816-6640
CEO
Colin Broom
Headquarters
-
Business Address
56 FITZWILLIAM SQUARE, DUBLIN, IRELAND 2
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001641640
About

Nabriva Therapeutics AG is a clinical-stage biopharmaceutical company. It engages in the research and development of novel antibiotics to treat infections, with a focus on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Description

Developing a novel antibiotic for bacterial pneumonia.